Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 4400

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 4

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Disease
  • Cancer
  • Therapeutic
  • Pharmaceuticals
  • Diagnostic Substances

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4400

License Grant
A licensor granted an exclusive non-transferable world-wide license to certain patents it owns. The technology is to be used to commercialize biomarkers for detection of Alzheimer’s Disease (AD).  The licensee is a newly formed bio-science company.  The licensor owns through an affiliate at least 20% of licensee.
License Property
Licensed Technology. The term Licensed Technology shall mean all trade secrets, know-how, and other confidential and proprietary information owned by Licensor or licensed to Licensor by Licensor on or subsequent to the Effective Date, to the extent covering any of the following:

(i) in vitro therapeutic test system that uses cultured human fibroblasts or any other method to detect and measure PKC and/or other assays with peripheral cells to predict the presence of Alzheimer’s Disease in humans, and all succeeding test formats (including test kits);

(ii) the PKC activators (including bryostatin, analogs, PUFAs, and other PKC activators) and their therapeutic applications in humans or animals;

(iii) the LDL or ApoE-based drug delivery system that is targeted to enhance access of all manner of drugs and therapeutics to the brain by facilitation of transport of such drugs across the Blood-Brain-Barrier in humans or animals; and

(iv) the carbonic anhydrase activators and their therapeutic applications in humans or animals

Effective August 28, 2013, licensee signed a statement of work (SOW) with licensor pursuant to the License Agreement, whereby the Company has contracted for the further development of its AD diagnostic product. The project is intended to validate each of three biomarkers in a heterogeneous patient population to determine sensitivity and selectivity parameters for each biomarker, or combination of biomarkers, to detect Alzheimer’s Disease. The three biomarkers to be evaluated are: the PKCe levels, the Erk1/2 ratios, and the fibroblast morphology test.

Field of Use
The term Field of Use shall mean the field of use of the Licensed IP in humans or animals for therapeutic or diagnostic applications for Alzheimer’s Disease or other cognitive dysfunctions.

IPSCIO Record ID: 6572

License Grant
Pursuant to an agreement dated February 9, 2009 between the Company, and the Licensor, a California Corporation, the Licensee, is obligated to make payments, from earnings generated from Research derived from the biological specimens from Parkinson's disease patients and control patients provided by the Licensor.
License Property
IP relates to biomarkers for Parkinson's disease.
Field of Use
The Field of Use apply to the healthcare industry.  Licensee has an ongoing collaboration with the Parkinson’s Institute to test known Parkinson’s Disease (PD) patients’ blood to identify biomarkers for Parkinson’s Disease from the human plasma proteome microarray marketed as PlasmaScanâ„¢.  Licensee is also using the H25K Whole Human Genome Microarray to examine PD samples and has identified the world’s first functional mRNA biomarkers for Parkinson’s Disease. An expanded patient study will be used to further validate the PD biomarkers.  Licensee is also working with Stanford University to test known Alzheimer’s patients’ blood to identify biomarkers for Alzheimer’s Disease using PlasmaScan and other tools.

IPSCIO Record ID: 27678

License Grant
The Austrailian Licensor grants the Austrailian Licensee during the Term: separate exclusive, non-transferable licenses under the Patents and under Project IP; separate non-exclusive, non-transferable licenses under the Licensor Background IP excluding the Patents: under the Intellectual Property rights in the Know-how; to Exploit the Licensed IP and Products in the Territory and within the Therapeutic Field and the Diagnostic Field; and a separate non-exclusive, non-transferable license under the Licensed IP to conduct research and development of Products,including the right to sub-license as permitted in this Agreement.
License Property
The Licensor is the owner of or otherwise authorised to use the Intellectual Property including the technologies known as Modulation of B-Tubulin in Tumour Cells, Modulation of Beta-Tubulin Expression in Tumour Cells and Method for Inhibiting Tumour Growth and Incidence.
Field of Use
The Licensee will use the IP Methods for detecting and modulating the sensitivity of tumor cells: Therapeutic Field  Human therapeutic use and specifically excludes biomarker analytical assays for human diagnostic, theranostic or prognostic use.

Diagnostic Field  The field of diagnostics, specifically, biomarker analytical assays for human diagnostic, theranostic or prognostic use.

Methods for detecting and modulating the sensitivity of tumor cells.

IPSCIO Record ID: 29096

License Grant
The Licensor,not-for-profit corporation, grants a non-exclusive subLicenses to such patents to the Licensee in the field of commercial diagnostic testing services for detection of UGT1A1 in humans effective April 14, 2006. The Licensee will pay an upfront fee and royalties.

The Licensor Licensed certain patents related to UGT1A1, from a University pursuant to a License Agreement dated November 18, 2005.

License Property
UGT1A1 is a hepatic enzyme primarily responsible for conjugation of bilirubin. UGT1A1 also catalyzes the glucuronidation of SN-38, the active metabolite of irinotecan and the main source of treatment-related toxicity.

US Issued Pat App No. 08/423,641, filing date 04/17/95, Patent No. 5,786,344
US Issued Pat App No. 09/251,274, filing date 02/16/99, Patent No. 6,395,481
US Issued Pat App No. 10/061,693, filing date 02/01/02, Patent No. 6,472,157

Field of Use
Field means commercial diagnostic testing services for detection of UGT1A1 in humans. Field does not include the research, development, manufacture, marketing, or sale of therapeutic products. Commercial diagnostic testing services shall include, but not be limited to, in-house laboratory tests pursuant to CLIA, clinical trials testing, and the manufacture, use and sale of diagnostic kits.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.